Study S003252

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of 28 Weeks to Investigate the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Followed by a 32-Week Extension (VESPER-1)

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT06712836
Acronym: VESPER-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 239
Start: 2024-10-09
Primary completion: 2025-07-03
Lead sponsor: Pfizer
Conditions: Obesity; Overweight or Obesity
Interventions: DRUG:MET097; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:C6491004

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 28: Part A [Baseline (last non-missing measurement prior to the first dose), Week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.